Results 151 to 160 of about 501,602 (328)
Transfer of multiple sclerosis into severe combined immunodeficiency mice by mononuclear cells from cerebrospinal fluid of the patients. [PDF]
Yukihiko Saeki+6 more
openalex +1 more source
Base editing: a novel cure for severe combined immunodeficiency. [PDF]
Ha TC, Morgan M, Schambach A.
europepmc +1 more source
Severe Combined Immunodeficiency Disease with Adenosine Deaminase Deficiency
Shinkichi Yokoyama+6 more
openalex +2 more sources
Control of human B cell tumor growth in severe combined immunodeficiency mice by monoclonal anti-B cell antibodies. [PDF]
Anne Durandy+5 more
openalex +1 more source
Abstract A reduced proportion of peripheral class‐switched memory B cells (CSM‐B cells) is presumed to indicate ineffective germinal activity. The extent that this finding corresponds to a plausible germinal center failure pathophysiology in patients not diagnosed with CVID or hyper IgM syndrome is not known.
Vijaya Knight+3 more
wiley +1 more source
Systemic therapy‐based split‐course stereotactic body radiation therapy
Abstract Purpose Given the therapeutic toxicity of concurrent chemoradiotherapy, the dose of chemotherapy is always limited. Hence, the question of how to administer adequate chemotherapy to synchronize stereotactic body radiation therapy (SBRT) treatment strategy for maximizing the benefits of neoadjuvant therapy to improve prognosis is a challenging ...
Rong Zheng+3 more
wiley +1 more source
Evaluation of temperature sensitivity of human papillomavirus type 11 by using the human xenograft severe combined immunodeficiency mouse model [PDF]
William Bonnez+4 more
openalex +1 more source
Abstract Aims miRNAs, small non‐coding RNAs, play key roles in gene regulation, cell differentiation and tissue development. They influence viral infection outcomes by directly interacting with viral genomes or modifying the host microenvironment. This study demonstrates miRNAs' ability to selectively suppress transcriptionally active erythroparvovirus,
Ganna Aleshcheva+5 more
wiley +1 more source
New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the ...
Alessandra Ghigo+22 more
wiley +1 more source